- Solid Tumors
- Pipeline Molecules
- Alliance Partners
Our mission is to provide healthcare professionals with unbiased clinical research information, easily.
Currently, you can access the following clinical trials being conducted worldwide:
The epigenetic modifier romidepsin is a potent class 1 selective histone deacetylase inhibitor.1-2?Altered expression, dysregulation, and mutations of histone deacetylase (HDAC) genes have been implicated in tumor development in cells of various cancers.3,4?In preclinical studies, HDAC inhibitors, such as romidepsin, prevent HDACs from removing acetyl groups, both allowing DNA to remain transcriptionally active (eg, tumor suppressor genes) and maintaining the acetylation of non-histone proteins (eg, genes involved in cell growth and differentiation).1,3,5?The downstream anti-cancer effects of HDAC inhibitors potentially include interference with cell cycle and mitosis, decreased cell motility, decreased angiogenesis, cell differentiation, and cell death.1,3,4,6
Romidepsin Hypothesized Mechanism of Action
Binding of romidepsin to HDACs has been hypothesized to result in various downstream anti-cancer effects, including in lymphoma.